ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1671

Cardiovascular Risk At Incidence Of Giant Cell Arteritis: A Population Based Retrospective Cohort Study

P. Deepak Udayakumar1, Arun K. Chandran1, Cynthia S. Crowson2, Kenneth J. Warrington3 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease and giant cell arteritis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Many systemic inflammatory rheumatic conditions are associated with increased cardiovascular (CV) risk. We aimed at assessing the CV risk at incidence of giant cell arteritis (GCA).

Methods: We retrospectively reviewed a population-based incidence cohort of GCA patients diagnosed between 1950 and 2009 based on American College of Rheumatology 1990 GCA classification criteria. We also included patients ≥ 50 years of age with elevation of erythrocyte sedimentation rate or C-reactive protein and computed tomography, magnetic resonance imaging or positron emission tomography evidence of large vessel vasculitis involving ascending aorta and its branches. We compared this cohort with age, sex and calendar year matched cohort from the same population. All subjects were longitudinally followed through all available community medical records until death, migration or April 30, 2013. Data was collected on all documented episodes of acute coronary syndrome (ACS) events prior to GCA incidence/index date and CV risk factors at GCA incidence/index date. Chi-square tests were used to compare characteristics between GCA and non-GCA cohort.

Results: We identified 245 patients in GCA cohort and 245 age, sex and calendar year matched patients in non-GCA cohort. At GCA incidence, 107 (44%) GCA subjects were on antihypertensives as opposed to 127 (52%) non-GCA subjects (p=0.08). Mean high density lipoprotein (HDL) was higher in GCA cohort [61.5 mg/dl; standard deviation (SD) 17.1] than non-GCA cohort (55.3 mg/dl; SD 17.9) (p=0.034). Mean triglycerides was lower in GCA cohort (124.2 mg/dl; SD 59.6) than non-GCA cohort (148.8 mg/dl; SD 77.5) (p=0.029). Mean low density lipoprotein (LDL) and total cholesterol were not different between the two cohorts. 23 (9.6%) subjects were on lipid lowering medication in GCA cohort as opposed to 39 (16.1%) in non-GCA cohort (p=0.032). No difference was noted in smoking status, obesity or chronic kidney disease between the two cohorts. Diabetes mellitus was present in 17 (6.9%) GCA subjects and 40 (16.3%) non-GCA subjects (p=0.001). Mean overall Framingham 10 year cardiovascular risk score was 30% (SD 19) in GCA subjects and 34% (SD 23) in non-GCA subjects (p=0.096) at incidence/index date. Positive family history of premature ACS was less frequent in GCA (2 of 26 subjects; 13%) than non-GCA cohort (10 of 32 subjects; 48%) (p=0.024). Occurrence of acute coronary syndrome (ACS) prior to GCA incidence/index date was similar between the two cohorts: 18 episodes (7.4%) in GCA cohort versus 17 episodes (6.9%) in non-GCA cohort (p=0.86).

Conclusion:  Multiple cardiovascular risk factors are more favorable at incidence of GCA when compared to non-GCA subjects of similar age and gender. Anti-hypertensives and lipid lowering medications are less frequently used in GCA subjects at incidence. Framingham 10 year cardiovascular risk may be lesser at GCA incidence although this did not achieve statistical significance in our study. As GCA is a disease that almost exclusively affects the elderly, there may be a component of healthy cohort bias causing this effect.


Disclosure:

P. D. Udayakumar,
None;

A. K. Chandran,
None;

C. S. Crowson,
None;

K. J. Warrington,
None;

E. L. Matteson,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-at-incidence-of-giant-cell-arteritis-a-population-based-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology